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Opinion statement 
Antimicrobial agent effectiveness continues to be threatened by the rise 
and spread of pathogen strains that exhibit drug resistance. This 
challenge is most acute in healthcare facilities where the well-established 
connection between resistance and sub-optimal antimicrobial use has 
prompted the creation of antimicrobial stewardship programs (ASPs). 
Mathematical models offer tremendous potential for serving as an 
alternative to controlled human experimentation for assessing the 
effectiveness of ASPs. Models can simulate controlled randomized 
experiments between groups of virtual patients, some treated with the 
ASP measure under investigation, and some without. By removing the 
limitations inherent in human experimentation, including health risks, 
study cohort size, possible number of replicates, and effective study 
duration, model simulations can provide valuable information to inform 
decisions regarding the design of new ASPs, as well as evaluation and 
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improvement of existing ASPs. To date, the potential of mathematical 
modeling methods in evaluating ASPs is largely untapped, and much 


































































































































Author	 Year	 Pathogen	 Infection	type	 Antimicrobial(s)	 Ref	#	
Chamchod	 2012	 MRSA	 Non‐specific Non‐specific	 (16)
Caudill	 2013,	2015	 MRSA	 Pneumonia	 Imipenem,	oxacillin	 (17,	18)	
D’Agata	 2012	 Non‐specific Non‐specific Non‐specific	 (19)
Deeny	 2015	 Healthcare‐acquired	MRSA	 None	(screening)	 Muporicin	 (20)	
Doan	 2015	 A.	baumannii Non‐specific	in	ICU Non‐specific	 (21)
Felton	 2013	 P.	aeruginosa	 Healthcare‐acquired	 Piperacillin‐tazobactam	 (22)	
pneumonia
Geli	 2012	 Non‐specific Non‐specific Non‐specific	 (23)
Grima	 2012	 C.	difficile	and	VRE Non‐specific Non‐specific	 (24)
Hurford	 2012	 P.	aeruginosa Non‐specific	in	ICU Non‐specific	 (25)
Kardaś‐





































Ternent	 2015	 Non‐specific Non‐specific Non‐specific	 (31)


























































































































































































































Initial therapy plan – dosage and frequency:  
None	of	the	search	results	investigate	this	decision	point.		
	





























Re- evaluate dosage and frequency: 
None	of	the	search	results	investigate	this	decision	point.		
	
Discontinuation of antimicrobial therapy:  
Seven	of	the	search	results	address	aspects	that		apply	to	this	decision	point.	Four	of	these	(16,	21,	23,	25)	
specifically	address	time‐duration	of	AMT,	while	the	other	three	(26,	28,	30)	consider	only	a	non‐specific	
reduction	in	overall	AM	consumption.	Of	these	seven	papers,	all	except	Geli	et	al.	(23)	are	detailed	under	“Will	
the	patient	receive	antimicrobial	treatment?”	above,	and	will	not	be	repeated	here,	with	the	exception	of	
Hurford	et	al.	(25),	because	it	includes	model	predictions	that	apply	to	this	decision	point,	but	not	the	
previous	one.		
● Geli	et	al.	(23):	
○ Key	assumptions:	Sensitive	bacteria	mutate	to	become	resistant	bacteria	at	a	fixed	
deterministic	rate.	The	resistant	bacteria	population	grows	at	the	same	rate	as	the	sensitive	
population,	but	is	assumed	to	die	at	a	faster	rate.	The	AM	concentration	is	constant	
throughout	the	treatment	period.	Both	strains	of	pathogen	are	killed	by	the	AM,	but	at	
different	rates.		
○ Model	type:	IHPM	of	interactions	between	susceptible	pathogen,	resistant	pathogen,	and	
immune	response.		
○ Model	predictions:	Risk	for	development	of	resistant	pathogens,	as	a	function	of	AM	use,	
differs	between	commensal	and	non‐commensal	bacteria.	For	commensals,	risk	is	greatest	
for	long	treatment	durations.	For	non‐commensals,	risk	is	greatest	for	intermediate	
treatment	durations.	
● Hurford	et	al.	(25):	
○ Key	assumptions:	See	previous	analysis.		
○ Model	type:	See	previous	analysis.		
○ Model	predictions:	Shorter	duration	of	AMTs	will	result	in	a	lower	number	of	patients	
colonized	with	the	resistant	strain	of	P.	aeruginosa.	
	
Conclusions 
	
Antimicrobial	resistance	will	likely	remain	as	a	significant	health	crisis	for	the	foreseeable	future.	Given	the	
mounting	evidence	connecting	AM	resistance	to	AM	use,	overuse,	and	misuse,	there	is	little	question	that	we	
must	wisely	utilize	our	AM	arsenal.	Antimicrobial	stewardship	programs	are	central	to	this	effort,	and	yet,	
recent	reports	indicate	that	fewer	than	half	of	the	acute	health	care	facilities	in	the	U.S.	currently	have	ASPs	
(34).	As	more	of	these	facilities	work	to	design	and	implement	ASPs,	they	must	choose	which	available	ASMs	
are	most	likely	to	be	effective	within	their	institution	and	local	community.	Mathematical	models	can	provide	
a	practical	and	economical	tool	for	simulating	controlled	experiments	to	predict	the	impact	of	ASMs,	without	
putting	humans	at	risk	while	providing	valuable	input	to	clinicians	as	they	work	to	optimally	choose	the	best	
drug,	mode	and	timing	of	administration,	and	treatment	duration.			
	
As	the	small	number	of	search	results	here	illustrates,	recent	work	that	leverages	the	advantages	of	
mathematical	modeling	in	ASP	development	and	assessment	is	limited.	Fully	two‐thirds	of	our	search	results	
investigate	the	impact	of	an	overall	reduction	in	AMs,	although	only	four	consider	distinctions	between	
different	AM	classes.	By	contrast,	few	or	none	of	these	studies	address	ASMs	related	to	the	other	therapy	
decision	points	(Table	2).		
	
Many	open	questions	remain	about	how	to	best	optimize	ASPs.	High	priority	points‐of‐focus	for	future	
modeling	investigations	should	include:	
 Minimization	of	the	time	duration	between	the	start	of	the	initial	therapy	protocol,	the	re‐evaluation	
and	de‐escalation	of	therapy	(e.g.	from	broad‐spectrum	to	narrow‐spectrum	antimicrobials),	and	the	
discontinuation	of	therapy.		
 The	effects	of	incomplete	compliance	with	ASP	guidelines.		
 Accounting	for	acute	care	facilities	within	the	larger	community	network.		
Results	from	mathematical	modeling	studies	that	holistically	analyze	the	decision	points	delineated	in	Table	2	
could	have	a	marked	effect	in	helping	to	reduce	the	problem	of	antimicrobial	resistance	in	healthcare	settings.	
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